Cargando…

Evolution of resistance to thyroid cancer therapy

Detalles Bibliográficos
Autor principal:	Nucera, Carmelo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032682/ https://www.ncbi.nlm.nih.gov/pubmed/27575377 http://dx.doi.org/10.18632/aging.101030

Ejemplares similares

Clonal Reconstruction of Thyroid Cancer: An Essential Strategy for Preventing Resistance to Ultra-Precision Therapy
por: McGonagle, Elizabeth R., et al.
Publicado: (2019)

A novel combined targeted therapy with bromodomain antagonist and MEK inhibitor in anaplastic thyroid cancer
por: Nucera, Carmelo
Publicado: (2019)

Targeting Thyroid Cancer Microenvironment: Basic Research and Clinical Applications
por: Nucera, Carmelo
Publicado: (2013)

Clinical Outcome, Role of BRAF(V600E), and Molecular Pathways in Papillary Thyroid Microcarcinoma: Is It an Indolent Cancer or an Early Stage of Papillary Thyroid Cancer?
por: Nucera, Carmelo, et al.
Publicado: (2012)

Effect of the micronutrient iodine in thyroid carcinoma angiogenesis
por: Daniell, Kayla, et al.
Publicado: (2016)

Role of Regulatory Non-Coding RNAs in Aggressive Thyroid Cancer: Prospective Applications of Neural Network Analysis
por: Iesato, Asumi, et al.
Publicado: (2021)

Thyroid Cancer: Toward Surgical Evolution
por: D’Amore, Annamaria, et al.
Publicado: (2021)

The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010)

Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment
por: Duquette, Mark, et al.
Publicado: (2013)

Therapy drives genomic evolution in metastatic cancer
por: Christensen, Ditte S., et al.
Publicado: (2023)

Corrigendum: Thrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells With BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor Microenvironment
por: Duquette, Mark, et al.
Publicado: (2020)

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E)
por: Antonello, Zeus A., et al.
Publicado: (2017)

Invasive follicular variant of papillary thyroid cancer harboring the NRAS mutation Q61K and presenting with bone metastasis—A case report
por: Mehrzad, Raman, et al.
Publicado: (2017)

Bacterial Antibiotic Resistance: The Most Critical Pathogens
por: Biondo, Carmelo
Publicado: (2023)

Drug Resistance and Novel Therapies in Cancers
por: Wang, Zhixiang
Publicado: (2020)

Anaplastic Thyroid Carcinoma: Molecular Tools for Diagnosis and Therapy
por: Garcia-Rostan, Ginesa, et al.
Publicado: (2015)

Evolution of Guidelines for Testosterone Replacement Therapy
por: Park, Hyun Jun, et al.
Publicado: (2019)

Differentiated Thyroid Cancer in Asians
por: Kim, Bo Hyun
Publicado: (2016)

Unfounded Reports on Thyroid Cancer
por: Chung, Jae Hoon
Publicado: (2014)

Updates in Thyroid Cancer Surgery
por: Sorrenti, Salvatore, et al.
Publicado: (2023)

PHIPing along: Evolution of PHIP as a cancer biomarker and a target for therapy
por: Kashani-Sabet, Mohammed, et al.
Publicado: (2018)

Protecting the mental health of healthcare workers during the COVID-19 emergency
por: Chirico, Francesco, et al.
Publicado: (2020)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Drug Resistance and Novel Therapies in Cancers in 2019
por: Wang, Zhixiang
Publicado: (2021)

Emerging concepts in cancer therapy: Mechanisms of resistance
por: Gupta, Seema, et al.
Publicado: (2022)

Drug Resistance and Novel Therapies in Cancers in 2020
por: Wang, Zhixiang
Publicado: (2023)

Evolution of intravitreal therapy for retinal and macular disorders
por: Panos, Georgios D.
Publicado: (2018)

Thyroid Cancer: Molecular and Modern Advances
por: Rosen, Jennifer E., et al.
Publicado: (2010)

Anaplastic Cancer of the Thyroid: The Viper in the Pit
por: Seshadri, Krishna G.
Publicado: (2019)

Towards precision medicine in thyroid cancer
por: Xiao, Haipeng, et al.
Publicado: (2020)

Recent Advances in Thyroid Cancer Research
por: Grimm, Daniela
Publicado: (2022)

Mechanisms of resistance to mitochondria-targeted therapy in pancreatic cancer
por: Boukalova, Stepana, et al.
Publicado: (2021)

Exosomes as versatile nanoscaled biocompartments in cancer therapy and/or resistance
por: Rahbar Saadat, Yalda, et al.
Publicado: (2022)

Special Issue: Resistance to Targeted Therapies in Human Cancer
por: Lee, Tae-Won, et al.
Publicado: (2023)

Evolution of systemic therapy for advanced-stage hepatocellular carcinoma
por: Hur, Moon Haeng, et al.
Publicado: (2022)

The World Association of Radiopharmaceutical and Molecular Therapy position statement on the initial radioiodine therapy for differentiated thyroid carcinoma
por: Dizdarevic, S, et al.
Publicado: (2019)

Radioiodine for thyroid cancer: sometimes, less is best
por: Padovani, Rosalia do Prado
Publicado: (2016)

New Diagnostic and Therapeutic Tools for Thyroid Cancer
por: Fröhlich, Eleonore, et al.
Publicado: (2013)

Special Issue: Genetic Perspectives in Thyroid Cancer
por: Silva, Susana Nunes
Publicado: (2021)

Thyroid cancer in the era of endocrine disrupting compounds
por: Preda, Cristina
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rhdfo7bit2mguja11hkr91tk5d